TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in distress levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Difference in pulse wave velocity measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reconstructions of the fiber tracts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Venous Stasis Ulcers Attaining Complete Wound Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Development of analgesic tolerance to morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: persistent inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: myocardial fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: myocardial stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Predictive value of procalcitonin in blood cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of adverse cardiac events
Endpoint domain: Adverse events/effects
Primary endpoint: Fatty acid composition of PMBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ex vivo cytokine production (IL-6, TNF-α, IL-10, interferon-γ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma CRP, IL-6 & fibrinogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma lipid profile (TAG, cholesterol, LDL & HDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse Event Grading
Endpoint domain: Adverse events/effects
Primary endpoint: undernutrition reporting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of orange fluorescent positive cells in voided urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mean change in apathy scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bond Lader mood scales
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Digit vigilance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Word recognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rapid Visual Information Processing (RVIP)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: fMRI blood oxygen level-dependent (BOLD) responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resting state functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: structural connectivity revealed by DTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Ventilator-Free Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Quality of Life at 3 and 12 months after discharge
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of cycles in six months of therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: coping flexibility
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PCR test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximal Inspiratory Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensory profile test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postrotary nystagmus test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in core - peripheral temperature gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression levels of mRNA and miRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic effectiveness of identified patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Attentional Functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of transfusion with allogenic blood products
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of spasticity in gastrocnemius
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of treatment emergent adverse events (TEAES)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of cellular graft failure or rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Response (CR) Rate as Assessed by Independent Review Committee (IRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recommended Phase II Dose (RP2D) of Glofitamab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in number of bowel movements per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Treated lesion response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events (AEs) and serious adverse events (SAEs) Reporting
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Anemia Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: vena cava inferior diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of ventricular arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of supraventricular arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improvement in jet lag symptoms
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Survival Rate at 30 Days
Endpoint domain: Mortality/survival
Primary endpoint: Survival Rate at 60 Days
Endpoint domain: Mortality/survival
Primary endpoint: Survival Rate at 100 Days
Endpoint domain: Mortality/survival
Primary endpoint: Survival Rate at 5 Years
Endpoint domain: Mortality/survival
Primary endpoint: Airway pepsin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who experienced an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who discontinued study drug due to an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase 2 Doses (RP2Ds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of symptoms and mood state
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hepatic Encephalopathy incidence post-TIPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coincidence rate between drug sensitivity test and objective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Vectors With Phrenic Nerve Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Subjects Achieving Complete Clearance of All Warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of participants survival to discharge
Endpoint domain: Mortality/survival
Primary endpoint: Hamilton Rating Scale for Depression (HRSD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neoadjuvant Rectal (NAR) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montgomery-Åsberg Depression Rating Scale (MADRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum observed plasma concentration (Cmax) of venetoclax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) for venetoclax up to 24 hours post-dose (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of nadroparine or heparin
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of nadroparine or heparin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Daily Headaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need of postoperative vasoactive support after LUTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of the Total WOMAC Score (WOMAC-T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of procedure performance in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in pain score at week 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Human Serum Bactericidal Activity Titers (hSBA) ≥ 4 or ≥ 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With hSBA Titers ≥ 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The hSBA Geometric Mean Titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Platelet count during delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline in sIgA at 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline in lactoferrin at 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline in sIgA at 21 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline in lactoferrin at 21 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of postoperative major respiratory complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: subjective wake after sleep onset
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Academic Performance: Grade Point Averages
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Malreduction of the tibiofibular joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in glycated haemoglobin (HbA1c) (percentage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in HbA1c (mmol/mol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Experiencing Significant Hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Significant Ventricular Arrhythmia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Significant Atrial Flutter
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Significant Bradycardia
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptance rate of suggested intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average Contact Force Exerted on the Heel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Pressure Index on the Heel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of Fluoride Ions in Saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline of the Cohen-Mansfield Agitation Inventory Short Version (CMAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Costs of asthma per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of PrEP Services Appointments Attended
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Who Received a PrEP Prescription
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Lid Margin Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-invasive Tear Break-up Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear Meniscus Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in proportion of patients with a low adherence score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: recurrence of arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response to Therapy (Reduction in CDAI Score and Inflammatory Markers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline Social Function
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Spirometry in liters or percentage evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CFQR and SNOT22 evolution
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Exacerbation evolution
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Clinical grading of the full face
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of senescent lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: infant emergency room use
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: number of infant overnight hospital stays
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: maternal wellbeing as assessed using the Edinburgh Postpartum Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Endurance exercise performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture
Endpoint domain: Mortality/survival
Primary endpoint: Time From Baseline to First Osteoporotic Clinical Hip Fracture (Adjudicated)
Endpoint domain: Mortality/survival
Primary endpoint: Time From Baseline to First Osteoporotic Clinical Non-Vertebral Fracture (Adjudicated)
Endpoint domain: Mortality/survival
Primary endpoint: Interdialytic weight gain (IDWG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing Aid Benefit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of DSW vs non-DSW drinking water
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Child Sexual Behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Samsca sodium correction rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of hLL1-DOX
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained objective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving a target sUA < 6.0 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients achieving an sUA reduction of ≥ 2.0 mg/dL from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute reduction in sUA from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CT Image Quality Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of combined gastric and duodenal ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ELISA Seropositivity Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effect site concentration of propofol at time of loss of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect site concentration of propofol at loss of response to painful stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Lens Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symbol Digit Modalities Test (SDMT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Parkinson's Disease Questionnaire-39 (PDQ-39)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Serum neutralizing antibody titers (NT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: In-stent late-loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: intensive care unit acquired weakness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antimicrobial Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bacterial concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of patients achieving Hb increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Antidepressant effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of CPG 7909 Injection
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of CPG 7909 Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall tumor response rate according to RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sway during quiet stance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stepping latency on push-and-release test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systematic Coronary Risk Estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of sexual dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of urinary dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Boston Functional Capacity Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: electroneurophysiological evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain activity assessed by fMRI scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tear Film Kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Controlled Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain/Disability Using the Oswestry Disability Index (ODI) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: No Device Failures
Endpoint domain: Adverse events/effects
Primary endpoint: Major Complications Defined as Major Vessel Injury or Neurological Damage
Endpoint domain: Adverse events/effects
Primary endpoint: Normal Neurological Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: anti-viral activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety evaluations (labs, ECG, blood pressure)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Lumbar Spine Bone Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in mean fluorescence intensity of PAC-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Trimethylamine N-oxide (TMAO) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Behavioural Intervention Rating Scale (BIRS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Isokinetic Maximal Voluntary Strength of the Plantar Flexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Free bilirubin serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of re-intubations after extubation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of endoscopic dilation sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of balloons
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Shoulder pain score decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes